ITeos Therapeutics Inc (NASDAQ: ITOS) is -32.71% lower on its value in year-to-date trading and has touched a low of $4.80 and a high of $18.13 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ITOS stock was last observed hovering at around $10.04 in the last trading session, with the day’s loss setting it -8.73%.
Currently trading at $1.31M, the stock is -0.43% and 17.89% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.03 million and changing 1034211% at the moment leaves the stock 19.93% off its SMA200. ITOS registered 30.47% gain for a year compared to 6-month gain of 35.04%. The firm has a 50-day simple moving average (SMA 50) of $8.4997 and a 200-day simple moving average (SMA200) of $8.355075.
The stock witnessed a 17.47% loss in the last 1 month and extending the period to 3 months gives it a 54.15%, and is 0.20% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.62% over the week and 2.50% over the month.
ITeos Therapeutics Inc (ITOS) has around 173 employees, a market worth around $383.50M and $35.00M in sales. Profit margin for the company is -373.75%. Distance from 52-week low is 108.75% and -44.73% from its 52-week high. The company has generated returns on investments over the last 12 months (-23.07%).
The EPS is expected to grow by 15.74% this year, but quarterly earnings will post -100.00% year-over-year. Quarterly sales are estimated to shrink -100.00% in year-over-year returns.
186.0 institutions hold shares in ITeos Therapeutics Inc (ITOS), with institutional investors hold 115.93% of the company’s shares. The shares outstanding are 38.27M, and float is at 35.88M with Short Float at 7.53%. Institutions hold 114.61% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 3.73 million shares valued at $55.37 million. The investor’s holdings represent 9.3983 of the ITOS Shares outstanding. As of 2024-06-30, the second largest holder is RA CAPITAL MANAGEMENT, L.P. with 3.52 million shares valued at $52.2 million to account for 8.8598 of the shares outstanding. The other top investors are ECOR1 CAPITAL, LLC which holds 3.25 million shares representing 8.1862 and valued at over $48.23 million, while BOXER CAPITAL, LLC holds 7.4231 of the shares totaling 2.95 million with a market value of $43.73 million.
ITeos Therapeutics Inc (ITOS) Insider Activity
The most recent transaction is an insider sale by Detheux Michel, the company’s Chief Executive Officer. SEC filings show that Detheux Michel sold 43,882 shares of the company’s common stock on Jun 09 ’25 at a price of $10.03 per share for a total of $0.44 million. Following the sale, the insider now owns 0.0 shares.
ITeos Therapeutics Inc disclosed in a document filed with the SEC on Jun 10 ’25 that Detheux Michel (Chief Executive Officer) sold a total of 43,883 shares of the company’s common stock. The trade occurred on Jun 10 ’25 and was made at $10.02 per share for $0.44 million. Following the transaction, the insider now directly holds 0.0 shares of the ITOS stock.
Still, SEC filings show that on Jun 09 ’25, Detheux Michel (Chief Executive Officer) disposed off 8,400 shares at an average price of $10.03 for $84252.0. The insider now directly holds 135,903 shares of ITeos Therapeutics Inc (ITOS).
